ATE432945T1 - Die aktivität von ccrl2 modulierende mittel und verfahren zu deren anwendung - Google Patents

Die aktivität von ccrl2 modulierende mittel und verfahren zu deren anwendung

Info

Publication number
ATE432945T1
ATE432945T1 AT04801256T AT04801256T ATE432945T1 AT E432945 T1 ATE432945 T1 AT E432945T1 AT 04801256 T AT04801256 T AT 04801256T AT 04801256 T AT04801256 T AT 04801256T AT E432945 T1 ATE432945 T1 AT E432945T1
Authority
AT
Austria
Prior art keywords
ccrl2
polypeptide
activity
methods
mip
Prior art date
Application number
AT04801256T
Other languages
English (en)
Inventor
Jonathon Mark Tinsley
Original Assignee
Oxagen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0328275A external-priority patent/GB0328275D0/en
Priority claimed from GB0403014A external-priority patent/GB0403014D0/en
Priority claimed from GB0418568A external-priority patent/GB0418568D0/en
Application filed by Oxagen Ltd filed Critical Oxagen Ltd
Application granted granted Critical
Publication of ATE432945T1 publication Critical patent/ATE432945T1/de

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52Assays involving cytokines
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/02Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Pathology (AREA)
  • Endocrinology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • AIDS & HIV (AREA)
  • Emergency Medicine (AREA)
AT04801256T 2003-12-05 2004-12-02 Die aktivität von ccrl2 modulierende mittel und verfahren zu deren anwendung ATE432945T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0328275A GB0328275D0 (en) 2003-12-05 2003-12-05 Ligands
GB0403014A GB0403014D0 (en) 2004-02-11 2004-02-11 Ligands
GB0418568A GB0418568D0 (en) 2004-08-19 2004-08-19 Ligands
PCT/GB2004/005057 WO2005057220A2 (en) 2003-12-05 2004-12-02 Agents modulating the activity of ccrl2 and methods of using the same

Publications (1)

Publication Number Publication Date
ATE432945T1 true ATE432945T1 (de) 2009-06-15

Family

ID=34681898

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04801256T ATE432945T1 (de) 2003-12-05 2004-12-02 Die aktivität von ccrl2 modulierende mittel und verfahren zu deren anwendung

Country Status (7)

Country Link
US (1) US7521194B2 (de)
EP (1) EP1692171B1 (de)
JP (1) JP4734256B2 (de)
AT (1) ATE432945T1 (de)
DE (1) DE602004021419D1 (de)
ES (1) ES2327126T3 (de)
WO (1) WO2005057220A2 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0513878D0 (en) * 2005-07-06 2005-08-10 Mars Inc Cat allergen
WO2007055636A1 (en) * 2005-11-08 2007-05-18 Astrazeneca Ab Single nucleotide polymorphisms in the ckrx gene associated with respiratory disease
WO2008028692A2 (en) * 2006-09-06 2008-03-13 Humanitas Mirasole S.P.A. Method for screening drug candidates for inflammatory diseases mediated by lps-inducible cc chemokine receptor mechanism
WO2010019811A2 (en) * 2008-08-15 2010-02-18 The Board Of Trustees Of The Leland Stanford Junior University Methods for screening for modulators of ccrl2

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE262914T1 (de) 1993-12-22 2004-04-15 Human Genome Sciences Inc Entzündungsproteine aus makrophagen mip-3, mip-4 und mip-1gamma
AU3134695A (en) 1995-05-05 1996-11-21 Human Genome Sciences, Inc. Human chemokine beta-8, chemokine beta-1 and macrophage infl ammatory protein-4
JP2000514295A (ja) 1996-07-05 2000-10-31 シェーリング コーポレイション 哺乳動物のケモカイン試薬
WO2001066598A2 (en) 2000-03-03 2001-09-13 Icos Corporation Chemoattractant receptor characterization and cell selection materials and methods and chemokine receptor ccr11 materials and methods
WO2002022856A2 (en) 2000-09-13 2002-03-21 Schering Corporation Uses of the mammalian ccl18 and related reagents
EP1352240A2 (de) 2001-01-18 2003-10-15 Rijksuniversiteit Groningen Klonierung und expression eines neuen mcp-rezeptors in glialzellen
WO2004045525A2 (en) * 2002-11-15 2004-06-03 Morehouse School Of Medicine Anti-chemokine and associated receptor antibodies and uses for inhibition of inflammation.
GB0306428D0 (en) 2003-03-20 2003-04-23 Oxagen Ltd Receptor proteins

Also Published As

Publication number Publication date
EP1692171A2 (de) 2006-08-23
WO2005057220A3 (en) 2006-02-02
JP4734256B2 (ja) 2011-07-27
US7521194B2 (en) 2009-04-21
ES2327126T3 (es) 2009-10-26
US20070036781A1 (en) 2007-02-15
DE602004021419D1 (de) 2009-07-16
WO2005057220A2 (en) 2005-06-23
JP2007520210A (ja) 2007-07-26
EP1692171B1 (de) 2009-06-03

Similar Documents

Publication Publication Date Title
ATE418729T1 (de) Verfahren zur charakterisierung von biomolekülen mittels resultat-gesteuerter strategie
DE60233142D1 (de) Verfahren und reagentien zum nachweis von endotoxin
ATE519106T1 (de) Verfahren zur analyse von tränenflüssigkeit
ES2192157T1 (es) Metodo y dispositivo para determinacion de posicion.
BRPI0002963B1 (pt) processo e dispositivo medidor eletroquìmico para medir uma concentração de analito em uma amostra.
ATE553845T1 (de) Testverfahren und vorrichtung hierfür
BRPI0307697A2 (pt) método para o monitoramento, estimativa e construção de equações para estimação da concentração de um analito selecionado dentro de uma amostra, método para a determinação do volume de uma amostra e de um conjunto de fatores ambientais presentes em um sistema eletroquímico, aparelho e método para a determinação da identidade de uma amostra em contato eletrolítico com um sistema eletroquímico
BR0007223A (pt) Dispositivo de teste, e, processos para construirum aparelho de teste de reação de amplificação deácido nucléico em dose unitária e para executaruma reação de amplificação de ácido nucleico
WO2004113896A3 (en) System and method for analysis of a biological fluid by the use electrical means
ATE306081T1 (de) Vorrichtung zur messung der konzentration eines analyts in einer flüssigkeit
ATE507524T1 (de) Durchführung von prüfungen an der betriebsmittelbenutzung von computerprogrammen
DE60330248D1 (de) Teststreifen zum analytnachweis und verwendungsverfahren
ATE514945T1 (de) Diagnoseverfahren für maul- und klauenseuche und diagnostischer kit
DE60328885D1 (de) Verfahren zur Beurteilung eines Krankheitzustandes mittels Nachweis von partikel- und nicht partikelgebundenen Nukleinsäuren in Blutplasma und -serum
ES2145924T3 (es) Procedimiento para detectar anticuerpos.
SE0004221D0 (sv) Metod och anordning för talanalys
ATE465410T1 (de) Vorrichtungen und verfahren zum nachweis von fruchtwasser in vaginalsekreten
ATE443775T1 (de) Hif-prolylhydroxylase-aktivitätstest
ES2154703T3 (es) Procedimiento para la deteccion especifica de un factor de coagulacion v activado con una estabilidad elevada frente a proteina c activada.
NO20040295L (no) Fremgansmate for testing av samhandlingen mellom en vaeskeprove og en respektiv fast prove
ATE432945T1 (de) Die aktivität von ccrl2 modulierende mittel und verfahren zu deren anwendung
ES2144604T3 (es) Inmunosubstraccion electroforetica capilar para clasificar y determinar las proteinas m.
NO20083133L (no) Dobbel transdermal analyttsensorsammensetning samt metoder for anvendelse derav
ATE421093T1 (de) Schnelle bestimmung verschiedener formen von hgf (heptocyte growth factor) in den körperflüssigkeiten
FI20010190L (fi) Nestenäytteiden testauksessa käytettävä menetelmä, menetelmää soveltava testiyksikkö sekä testiyksiköitä sisältävä järjestelmä

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties